Protecting Cell and Gene Therapies in the Cold Chain

When:  Nov 9, 2022 from 08:00 to 09:00 (PT)


Protecting Cell and Gene Therapies in the Cold Chain including Primary Packaging, Storage and Transport Equipment and Components

Presented by the ISCT Process Development & Manufacturing Committee

Sponsored by BioLife and W.L. Gore & Associates

 

Webinar Description:

In the second half of 6-part Cold Chain Webinar Series, we will cover common solutions to issues encountered in logistics and supply of getting ATMPs to intended destinations and patients.  Part 4 revisits formulation and container selection by addressing how these considerations affect shipping options and product custody.

Key Learning Objectives:

  • Explore various durability tests and considerations on primary, secondary, and transport packaging for cell and gene products
  • Understand the importance of cell therapy formulation and its impact on product performance during cryopreservation, storage, and transport
  • Gain an introduction to Chain of Identity and Chain of Custody tracking documentation and why this is an important industry guidance


Chaired By: 


Maria_headshot_2019_No__1.jpg

Dr. Shannon Eaker, PhD
Chief Technology Officer
Xcell Biosciences
United States

 
Dr. Shannon Eaker is the Chief Technology Officer at Xcell Biosciences. He earned his Ph.D. from the University of Tennessee, Knoxville in Biochemistry, Cellular and Molecular Biology. His expertise is primarily focused on T-cell, hematopoietic stem cell (HSC), undifferentiated embryonic stem (ES) and induced pluripotent stem (iPS) cell biology. Shannon has built and supported process development and manufacturing activities and platforms within cell and gene therapy. Prior to Xcell, Shannon was with Cytiva (formerly GE Healthcare) Cell and Gene Therapy where he spent more than 12 years. He is a member of the International Society for Cell Therapy (ISCT) Process Development and Manufacturing (PDM) committee and has authored numerous papers within the field of cell and gene therapy and regenerative medicine.







 

Shopper-Rod_Reitze_259-modified.png

Sean Werner, PhD
Chief Technology Officer
BioLife Solutions
United States

Sean Werner is the Chief Technology Officer - Cell Processing at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the CGT industry. Sean received his Ph.D. from Purdue University in Biology, followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly. Sean has previous experience filling various roles in the global regulatory and general management functions supporting medical devices, autologous cell therapy, and single-use disposable development programs. In his 15 years working in the life science industry, he has guided pre-clinical and clinical testing and submission strategies leading to the global commercialization of multiple medical devices and bioprocessing tools.

 

Shopper-Rod_Reitze_259-modified.png

Bill Shingleton, PhD
Director, Applications and Biology: Cell and Gene Therapy R&D
Cytiva
United Kingdom

 

Bill is passionate about delivering Advanced Therapeutic Medicinal Products (ATMPs) to patients. Focused on developing technology that will enable successful translation and commercialization.

As an experienced Biological Scientist, with a background in inflammation, the biology of ageing and connective tissues, he is applying this research knowledge in the fields of auto-immune, degenerative diseases and oncology. His experience was gained in academia at the Universities of Cambridge and Newcastle-upon-Tyne, combined with 20 years of industrial research with Unilever R&D, GE Healthcare Life Sciences and now Cytiva. Recent roles have been supporting the Cell Therapy Industry through the application of in-vivo imaging to enable safety, efficacy and mode of action studies. He is now driving the development of tools and technology for cell therapy manufacturing and cryo-preservation. In his current role, he leads a global team of biologists and engineers developing equipment, consumables, software and processes that enable the manufacture of cell and gene therapies.


Cold_Chain_Webinar.png

#Webinar
More information

Location

Online Instructions:
Url: http://us06web.zoom.us/webinar/register/WN_jBcRUVQVRhGAWejcdNMfrg
Login: Register through the link above.